Pages that link to "Q33986236"
Jump to navigation
Jump to search
The following pages link to Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia (Q33986236):
Displaying 50 items.
- Midostaurin: an emerging treatment for acute myeloid leukemia patients (Q26749271) (← links)
- Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy (Q26749870) (← links)
- Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities (Q26863756) (← links)
- Progress in acute myeloid leukemia (Q27024006) (← links)
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? (Q27028163) (← links)
- The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine (Q27700733) (← links)
- Novel therapeutic options in Acute Myeloid Leukemia (Q28069889) (← links)
- Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia (Q28075654) (← links)
- Secondary mutations as mediators of resistance to targeted therapy in leukemia (Q28087213) (← links)
- FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations (Q28289859) (← links)
- Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer (Q28538435) (← links)
- Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics (Q28544659) (← links)
- Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients (Q33555287) (← links)
- Emerging therapies for acute myeloid leukemia (Q33576363) (← links)
- Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia (Q33710062) (← links)
- Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. (Q33749036) (← links)
- Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia (Q33767026) (← links)
- Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia (Q33770125) (← links)
- Molecular therapy for acute myeloid leukaemia (Q33925672) (← links)
- Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia (Q33943277) (← links)
- The Biology and Targeting of FLT3 in Pediatric Leukemia (Q34229555) (← links)
- The Future of Targeting FLT3 Activation in AML. (Q34555386) (← links)
- Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia (Q34573775) (← links)
- Gene mutations and molecularly targeted therapies in acute myeloid leukemia. (Q34647741) (← links)
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome (Q35224437) (← links)
- Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. (Q35525811) (← links)
- Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions (Q35750567) (← links)
- A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients (Q35793176) (← links)
- Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. (Q35857472) (← links)
- Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia (Q36356082) (← links)
- Is targeted therapy feasible in acute myelogenous leukemia? (Q36416358) (← links)
- CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. (Q36545966) (← links)
- Recent advances and novel agents for FLT3 mutated acute myeloid leukemia (Q37043763) (← links)
- Acute myeloid leukemia: advancing clinical trials and promising therapeutics (Q37221579) (← links)
- Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers (Q37325725) (← links)
- Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia (Q37338371) (← links)
- The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia (Q37706488) (← links)
- FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia (Q38026453) (← links)
- FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance (Q38101284) (← links)
- Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD acute myeloid leukemia: an update. (Q38168893) (← links)
- Evolving treatment strategies in patients with high-risk acute myeloid leukemia (Q38179026) (← links)
- Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? (Q38182335) (← links)
- Novel therapeutics in acute myeloid leukemia (Q38196346) (← links)
- Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way? (Q38196347) (← links)
- Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it? (Q38199056) (← links)
- FLT3 inhibitors in AML: are we there yet? (Q38200564) (← links)
- The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond (Q38216649) (← links)
- Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years (Q38232465) (← links)
- Translational implications of somatic genomics in acute myeloid leukaemia. (Q38235586) (← links)
- Targeting FLT3 to treat leukemia (Q38251339) (← links)